Saitu Biotechnology: Holding subsidiary receives CEP certificate for dexamethasone raw material drug.

Saitu Biology announced on February 13th that its controlling subsidiary, Suyi Pharmaceutical, has recently received a Certificate of Suitability of the European Pharmacopoeia for the active pharmaceutical ingredient, Betamethasone. Betamethasone is a corticosteroid medication mainly used to treat allergies and autoimmune inflammatory conditions. It helps to reduce inflammation in the body, prevents tissue damage caused by excessive inflammation, and also suppresses overactive immune responses and allergic reactions.